share_log

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)

SEC ·  May 16 05:01

Summary by Moomoo AI

Biodexa Pharmaceuticals PLC has announced the distribution of its Annual Report for the fiscal year ending December 31, 2023, along with the Notice of Annual General Meeting (AGM) to its shareholders. The announcement, made on May 15, 2024, includes the provision of proxy forms for both ordinary shareholders and holders of American Depositary Shares to participate in the upcoming AGM. The meeting is scheduled for June 13, 2024, at the company's registered office in Cardiff, United Kingdom. The documents related to the Annual Report and AGM, including proxy forms, have been attached as exhibits to the company's Form 6-K filing with the United States Securities and Exchange Commission for May 2024.
Biodexa Pharmaceuticals PLC has announced the distribution of its Annual Report for the fiscal year ending December 31, 2023, along with the Notice of Annual General Meeting (AGM) to its shareholders. The announcement, made on May 15, 2024, includes the provision of proxy forms for both ordinary shareholders and holders of American Depositary Shares to participate in the upcoming AGM. The meeting is scheduled for June 13, 2024, at the company's registered office in Cardiff, United Kingdom. The documents related to the Annual Report and AGM, including proxy forms, have been attached as exhibits to the company's Form 6-K filing with the United States Securities and Exchange Commission for May 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more